Mark Exley | CSO
LIfT Biosciences

Mark Exley, Ph.D., is LIfT’s Chief Scientific Officer and Visiting Professor at Imperial College. He was Harvard Faculty for about 20 years and has over 40 years’ Immunology expertise, particularly Innate Immunology. He co-founded NKT Therapeutics and MiNK Therapeutics and is former CSO of Imvax. He has co-raised $160m+, taken two biotechs to or close to IPO, published 130+ papers and serves on major journal editorial boards. Mark received his BS from Imperial College, MS from King’s College, and PhD. from the Institute of Cancer Research in London and completed his post-doctoral fellowship at the Dana Farber Cancer Institute, Boston.